ADPT

Business Context and Reporting Period

Company: Adaptive Biotechnologies Corp (ADPT)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Adaptive Biotechnologies operates two primary segments: the Minimal Residual Disease (MRD) business, centered on the clonoSEQ diagnostic test for lymphoid malignancies, and the Immune Medicine (IM) business, which leverages proprietary data and sequencing to map T-cell receptors (TCRs) to antigens for drug discovery and diagnostics.

Key Financial Metrics

Note: Cash balances exclude $13.1 million held by Digital Biotechnologies, Inc.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 55% year-over-year, driven primarily by a 46% increase in MRD revenue ($212.3 million) and a 93% increase in Immune Medicine revenue ($64.6 million).
• MRD Segment Performance: clonoSEQ test volume grew 39% to 105,587 tests. MRD Adjusted EBITDA improved from a loss of $41.2 million in 2024 to a profit of $15.2 million in 2025.
• Immune Medicine Segment Performance: Revenue growth was significantly impacted by the termination of the Genentech collaboration agreement, which accelerated the recognition of $41.3 million in deferred revenue. Immune Medicine Adjusted EBITDA improved from a loss of $24.4 million to a profit of $10.3 million.
• Profitability Improvement: Net loss narrowed significantly by $100.1 million compared to 2024, reflecting revenue growth and cost management.
• Cost of Revenue: Decreased slightly by 1% to $71.4 million, improving the gross margin profile despite higher volume.

Guidance, Outlook, and Risks

• Collaboration Termination: The Genentech collaboration was terminated in August 2025 (effective February 2026). While this accelerated revenue recognition in 2025, the company expects Immune Medicine revenue to decrease in the short term as it transitions to other data licensing and target discovery agreements.
• New Partnerships: In December 2025, Adaptive entered into two non-exclusive agreements with Pfizer to leverage its TCR discovery platform for rheumatoid arthritis and broader immunology applications.
• Reimbursement: Medicare coverage for clonoSEQ expanded to include single time-point testing for Mantle Cell Lymphoma (MCL) recurrence monitoring. The Medicare episode rate increased to $8,029 (a 17% increase) effective January 2025.
• Liquidity: Management believes current cash and marketable securities are sufficient to fund operations for at least the next 12 months.
• Key Risks:
  • Regulatory: Potential changes in FDA regulation regarding Laboratory Developed Tests (LDTs) could increase compliance costs.
  • Reimbursement: Reliance on third-party payors for coverage and adequate reimbursement rates for clonoSEQ.
  • Supply Chain: Dependence on single suppliers (e.g., Illumina) for critical sequencing equipment and reagents.
  • Debt Obligations: The Revenue Interest Purchase Agreement with OrbiMed requires quarterly payments based on 5% of GAAP revenue, impacting cash flow.

Investor Verification Checklist

• Genentech Revenue Run-Rate: Verify the sustainability of Immune Medicine revenue post-Genentech termination and the progress of the new Pfizer agreements.
• clonoSEQ Penetration: Monitor test volume growth rates and payor coverage expansion in Non-Hodgkin Lymphoma (NHL) subtypes beyond DLBCL and MCL.
• Operating Leverage: Assess whether the reduction in operating cash burn can be sustained as sales and marketing expenses increase to drive adoption.
• Revenue Interest Liability: Review the impact of the 5% revenue interest payment on future free cash flow and the timeline for full repayment of the OrbiMed obligation.
• Regulatory Landscape: Track developments regarding the FDA's LDT final rule and its potential impact on the company's laboratory operations and cost structure.